Vancomycin and home health care

Emerging Infectious Diseases

Volumn 11, Issue 10, 2005, Pages 1558-1564

  Fraser, Thomas G ^a,d   Stosor, Valentina ^a   Wang, Qiong ^b   Allen, Anne ^c   Zembower, Teresa R ^a  

^a NORTHWESTERN UNIVERSITY   (United States)

^b UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

^c NORTHWESTERN MEMORIAL HOSPITAL   (United States)

^d LERNER RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

VANCOMYCIN;

ADULT; ADVISORY COMMITTEE; AGED; AGING; ANTIBIOTIC RESISTANCE; ANTIBIOTIC THERAPY; ARTICLE; BACTERIUM CULTURE; CHRONIC DRUG ADMINISTRATION; COHORT ANALYSIS; DRUG DOSE REGIMEN; DRUG USE; EMPIRIC THERAPY; EMPIRICISM; FEMALE; HOME CARE; HOSPITAL DISCHARGE; HOSPITAL INFECTION CONTROL ADVISORY COMMITTEE; HUMAN; INFECTION CONTROL; LONG TERM CARE; MAJOR CLINICAL STUDY; MALE; MALIGNANT NEOPLASTIC DISEASE; MEDICAL SERVICE; MICROBIOLOGICAL EXAMINATION; PARENTERAL DRUG ADMINISTRATION; POSTOPERATIVE CARE; PRACTICE GUIDELINE; PUBLIC HEALTH; WOUND;

EID: 25644436409     PISSN: 10806040     EISSN: None     Source Type: Journal    
DOI: 10.3201/eid1110.050336     Document Type: Article

References (29)

1. Wilhelm MP, Estes L. Symposium on antimicrobial agents-Part XII. Vancomycin. Mayo Clin Proc. 1999;74:928-35.
2. Ena J, Dick RW, Jones RN, Wenzel RP. The epidemiology of intravenous vancomycin usage in a university hospital. JAMA. 1993;269:598-602.
3. Fridkin SK, Edwards JR, Pichette SC, Pryor ER, McGowan JE Jr, Tenover FC, et al. Determinants of vancomycin use in adult intensive care units in 41 United States hospitals. Clin Infect Dis. 1999;28:1119-25.
4. Centers for Disease Control and Prevention. Nosocomial enterococci resistant to vancomycin-United States, 1989-1993. MMWR Morb Mortal Wkly Rep. 1993;42:597-9.
5. Centers for Disease Control and Prevention. Staphylococcus aureus resistant to vancomycin-United States, 2002. MMWR Morb Mortal Wkly Rep. 2002;51:565-7.
6. Chang S, Sievert DM, Hageman JC, Boulton ML, Tenover FC, Downes FP, et al. Infection with vancomycin-resistant Staphylococcus aureus containing the vanA resistance gene. N Engl J Med. 2003;348:1342-7.
7. Centers for Disease Control and Prevention. Recommendations for preventing the spread of vancomycin resistance. Recommendations of the Hospital Infection Control Practices Advisory Committee (HICPAC). MMWR Morb Mortal Wkly Rep. 1995;44:1-13.
8. Shlaes DM, Gerding DN, John JF Jr, Craig WA, Bornstein DL, Duncan RA, et al. Society for Healthcare Epidemiology of America and Infectious Disease Society of America Joint Committee on the Prevention of Antimicrobial Resistance: guidelines for the prevention of antimicrobial resistance in hospitals. Clin Infect Dis. 1997;18:275-91.
9. Jarvis WR. Preventing the emergence of multidrug-resistant microorganisms through antimicrobial use controls: the complexity of the problem. Infect Control Hosp Epidemiol. 1996;17:490-5.
10. Gould IM. A review of the role of antibiotic policies in the control of antibiotic resistance. J Antimicrob Chemother. 1999;43:459-65.
11. Hamilton CD, Drew R, Janning S, Latour JK, Hayward S. Excessive use of vancomycin: a successful intervention strategy at an academic medical center. Infect Control Hosp Epidemiol. 2000;21:42-5.
12. Singer MV, Haft R, Barlam T, Aronson M, Shafer A, Sands KE. Vancomycin control measures at a tertiary-care hospital: impact of interventions on volume and patterns of use. Infect Control Hosp Epidemiol. 1998;19:248-53.
13. Doern GV, Heilmann KP, Huynh HK, Rhomberg PR, Coffman SL, Brueggemann AB. Antimicrobial resistance among clinical isolates of Streptococcus pneumoniae in the United States during 1999-2000, including a comparison of resistance rate since 1994-1995. Antimicrob Agents Chemother. 2001;45:1721-9.
14. Salgado CD, Farr BM, Calfee DP. Community-acquired methicillin-resistant Staphylococcus aureus: a meta-analysis of prevalence and risk factors. Clin Infect Dis. 2003;36:131-9.
15. Tice AD, Rehm SJ, Dalovisio JR, Bradley JS, Martinelli LP, Graham DR, et al. Practice guidelines for outpatient parenteral antimicrobial therapy. Clin Infect Dis. 2004;38:1651-72.
16. Charlson ME, Pompei P, Ales KL, MacKenzie CR. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis. 1987;40:373-83.
17. Deyo RA, Cherkin DC, Ciol MA. Adapting a clinical comorbidity index for use with ICD-9 CM administrative databases. J Clin Epidemiol. 1992;6:613-9.
18. Evans ME, Kortas KJ. Vancomycin use in a university medical center: comparison with Hospital Infection Control Practices Advisory Committee guidelines. Infect Control Hosp Epidemiol. 1996;17:356-9.
19. Watanakunakorn C. Prescribing pattern of vancomycin in a community teaching hospital with low prevalence of vancomycin resistant enterococci. Infect Control Hosp Epidemiol. 1997;18:767-9.
20. Roghmann MC, Perdue BD, Polish L. Vancomycin use in a hospital with vancomycin restriction. Infect Control Hosp Epidemiol. 1999;20:60-3.
21. Lipsky BA, Baker CA, McDonald LL, Suzuki NT. Improving the appropriateness of vancomycin use by sequential interventions. Am J Infect Control. 1999;27:84-91.
22. Kwan T, Lin F, Ngai B, Loeb M. Vancomycin use in 2 Ontario tertiary care hospitals: a survey. Clin Invest Med. 1999;22:256-64.
23. Jarvis WR. Epidemiology, appropriateness, and cost of vancomycin use. Clin Infect Dis. 1998;26:1200-3.
24. Sinkowitz RL, Keyserling H, Walker TJ, Holland J, Jarvis WR. Epidemiology of vancomycin usage at a children's hospital, 1993 through 1995. Pediatr Infect Dis J. 1997;16:485-9.
25. Paskovaty A, Pflomm JM, Myke N, Seo SK. A multidisciplinary approach to antimicrobial stewardship: evolution into the 21st century. Int J Antimicrob Agents. 2005;25:1-10.
26. Classen DC, Burke JP, Wenzel RP. Infectious diseases consultation: impact on outcomes for hospitalized patients and results of a preliminary study. Clin Infect Dis. 1997;24:468-70.
27. Byl B, Clevenbergh P, Jacobs F, Struelens MJ, Zech F, Kentos A, et al. Impact of infectious diseases specialists and microbiological data on the appropriateness of antimicrobial therapy for bacteremia. Clin Infect Dis. 1999;29:60-6.
28. Lee CE, Zembower TR, Fotis MA, Postelnick MJ, Greenberger PA, Peterson LR, et al. The incidence of antimicrobial allergies in hospitalized patients: implications regarding prescribing patterns and emerging bacterial resistance. Arch Intern Med. 2000;160:2819-22.
29. Tice AD, Hoaglund PA, Nolet B, McKinnon PS, Mozaffari E. Cost perspectives for outpatient intravenous antimicrobial therapy. Pharmacotherapy. 2002;22:63S-70S.